78image/iStock via Getty Images It is a common occurrence to see the market fail to react to positive data or updates from small-cap healthcare companies. Admittedly, most of these companies are still very far from approval and are often undercapitalized to get their programs through the FDA and onto the market. However, I still get baffled when I see a company post clinical data that suggests the...
78image/iStock via Getty Images It is a common occurrence to see the market fail to react to positive data or updates from small-cap healthcare companies. Admittedly, most of these companies are still very far from approval and are often undercapitalized to get their programs through the FDA and onto the market. However, I still get baffled when I see a company post clinical data that suggests the drug/biologic/device/tech outperforms the standard of care in a huge market. Thankfully, some of these occurrences have allowed me to buy some shares at an apparent discount and eventually bank significant profit down the line as later-stage data confirms what was seen in the earlier studies. Well, Cardiff Oncology ( CRDF ) might turn out to be a great example after the market appeared to shrug off their recent Phase II data for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC). Five months ago, I wrote an article where I pointed out this data release to be a big catalyst for Cardiff, but perhaps I'm missing something. For me, the onvansertib in this dataset and conference call discussion suggests it is a drug that has a legitimate pathway to becoming a first-line standard-of-care backbone. As a result, I'm looking to take advantage of the market's lack of response and will look to add during this period of market volatility. I intend to review onvansertib's Phase II results and what the implications are for the drug, as well as the company. In addition, I discuss why I think the market reacted negatively to the data and the share price hasn't recovered. Then, I will point out some downside risks that investors need to consider when managing their CRDF position. Finally, I take a look at the daily chart to see if I can identify an opportunity to take advantage of the market's slip-up. Phase II Results The big headline for onvansertib's Phase II results was the 72% objective response rate (ORR), which is well above the 40%-45% range that is seen amon...
Broadcom (NasdaqGS:AVGO) has signed multi-year AI chip and infrastructure agreements with Google and Anthropic. The deals run through 2031 and cover exclusive custom silicon design and supply for next generation AI platforms. The arrangements include AI accelerators and networking hardware that support large scale AI workloads. For investors watching AI infrastructure, this positions Broadcom, a m...
Broadcom (NasdaqGS:AVGO) has signed multi-year AI chip and infrastructure agreements with Google and Anthropic. The deals run through 2031 and cover exclusive custom silicon design and supply for next generation AI platforms. The arrangements include AI accelerators and networking hardware that support large scale AI workloads. For investors watching AI infrastructure, this positions Broadcom, a major provider of custom chips and networking gear, closer to the core of how large models are...